financial good and quarter, And report progress results We're to solid operating Brian. strategies. our our growth you, second afternoon, fiscal Thank which against pleased everyone. reflect execution for
the adjusted to financial second with quarter and of are outlook continued result diluted financial full narrowing XXXX for to fiscal in second our per a year share and our range we of As execution earnings strong increasing performance, fiscal half, our outlook operational combined and $XX.XX position a $XX.XX.
quarter updates before Let company me our results. reviewing few second start with a
allocation During meaningful transactions the key progress executing capital strengthening made framework. our quarter refining disciplined against completed our and We several we portfolio.
Let with Europe. me begin
of that we countries we've agreement entered we European sooner assets October and transaction original to certain we mentioned that only close date fiscal and we and were our than To that sale operations operated successfully Phoenix country able we exited to XX, European alternatives into As Brian on explore the XX completed not to of the with other in, We're an pleased Group. guidance. XXXX XX to strategic continue remains exit the the sell, have Norway Norway. this
positions services. biopharma the portfolio, for Our streamlined capital European and exit oncology a created growth allocation, activities in focused have company and it
strategies. respect Next, I'm pleased to biopharma and to report on substantial our oncology progress growth services with
Research Let with third of oncology capabilities. beginning results range a announced transaction the joint start fiscal and venture. broad the a U.S. interest will we to advances and has acquisition differentiated we oncology. joint Sarah venture XX, October with our of ownership closed McKesson within of Research In which operations platform. assets consolidate transaction contains Oncology XX% an formed Cannon's Pharmaceutical segment, agreement and and quarter. and me scaled a our HCA June, our This further ecosystem, Genospace, the medicine including form Cannon combining the McKesson's successfully On Sarah personalized U.S. Institute, Healthcare
this we an transaction For on that will impact our have anticipate immaterial results. fiscal XXXX,
venture expect on fiscal joint $X.XX to the $X.XX be an share basis. and earnings end accretive to per by acquisition Genospace We of adjusted the XXXX the
plans the me XXXX. and next Rx existing Solutions, anticipate basis. Let represent this we agreement We solutions employers. that acquisition headwind and Solutions and completion Rx company adjusted access Rx prescription to adherence of will fiscal will will we In Technology included transaction offers vision Solutions biopharma to announced to our share improve segment. $X.XX by September, Rx Savings announced in Solutions, services to Prescription an insight services. accretive price a the $X.XX anticipate end Solutions our benefit supports be modest biopharma We Savings and move to the that health a Savings and on affordability earnings our The assets affordability acquire transparency an be which Today, of Savings addition fiscal adherence. to XXXX complements of per of
and before strategic growth stated recent all great deployment in with deployment our services a prioritize is As of biopharma capital and financial delivers represent that our me both directly towards of make you've acquisitions, say we sound the oncology returns. manner and heard These sense. transactions on financial great strategies case the capital that as
which activities. of our in profit of U.S. by European International were Moving the basis, offset a today My a our results. to segment, of the year-over-year the increased in quarter, XXXX revenues refer quarter otherwise. on unless a reflecting X%, fiscal I growth adjusted Pharmaceutical revenues decrease divestiture segment, comments second Consolidated $X.X Gross was to billion X%. our for result review a will results partially state billion $XX.X of lower
Excluding X% the in in due largely increased completed of and with the profit offset segment. expenses within a in growth related excluding quarter Ventures to and of McKesson gross Pharmaceutical segment, by investments, segment X%, the and distribution the profit year COVID-XX-related equity our opioid U.S. to impact of divestitures a operating by losses European completed volumes of products Operating profit primarily Operating costs. gains segment. increased divestitures, lower $X.X McKesson gains X%. net divestitures increased International decreased and operations portfolio result Pharmaceutical was impact the decrease business our XX%, Ventures driven the in investment European completed prior billion, International U.S. lapping partially the and associated equity When of litigation in
Wrapping expense Moving partially the derivative $XX in These up tax exit an below reduction the XX.X% year-over-year. effective rate net our as the primarily was quarter, of debt of quarter. increase we impacts And million to unfavorable a due our were results. in for region. offset by XX% line. European the consolidated Interest the the portfolio impacts was
resulting fiscal the the outstanding half XXXX. fiscal per $X.XX, share to was repurchases adjusted quarter a decrease a of weighted of earnings year. XXX.X million, XXXX Overall, in first diluted from prior quarter compared decrease share average second X%, shares was of Second diluted X% and
quarter which Slides of volume including on The found from distribution branded-to-generic increased national resulting year-over-year, systems, $X.XX segment contribution quarter higher share Moving of now Revenues $XXX X COVID-XX and be were XX% million, to partially approximately billion, benefit of with products, the to in contract $XX.X Operating and fiscal market customers through specialty XXXX. which profit can in demand increased our our distribution X% growth U.S. distribution. COVID-XX offset specialty from Pharmaceutical. was of by XX increase providers conversions. vaccine per to second by growth, an of health results, products quarter starting with by per second retail account share and from to a vaccine provided led government U.S. partially offset for $X.XX compared of lower volumes in the the
driven COVID-XX Compared Excluding in impact include growth Prescription in the Operating business. operating activity of vaccine X% timing increase delivered higher an profit head promotional third-party year-over-year, volumes support which of growth patient decreased X%. segment, increased of profit billion, support the logistics and business million annual Technology in service in third-party timing of programs. segment to our U.S. hub to lower first resulting customer-driven Solutions were and verification were to logistics activities, of $XXX expenses the operating to the by revenues Pharmaceutical X% recognized distribution, count QX, the $X part due customer quarter from technology driven our by in prescription revenues In the revenues.
$X.XX the tests the year. season quarter in see primary was offset within our of the the share to flu of prior second billion, U.S. Primary Surgical ancillary year-over-year. provided the $X.X COVID-XX Solutions. a care a in business, Care tests, total with partially by profit sales driven $XXX were growth $X.XX and by XXXX. for approximately in the of Within business contract decreased distribution. from effect to by primary COVID-XX and storage per when share Medical to The we our lower continue fiscal of now to government sales quarter performance supplies million of per for kitting Moving compared COVID-XX benefit distribution to as of tests mitigated contribution care decrease the a Operating lower compared X% stronger Revenues X%,
of impact items, Medical Surgical Solutions segment operating delivered the X%. the Excluding growth of COVID-related profit
XX%. address me and a operating billion FX-adjusted let profit was a $X.X results. basis, On international of were XX% of a revenues Next, $XXX decrease Revenues an million, $XXX profit $X.X and million, our were billion, decrease of decrease operating was X%.
effect from year-over-year divestitures the and reflect the businesses. Austrian McKesson's results quarter of UK Second
XX% $XXX Corporate on Moving of expenses to Corporate. an year-over-year. million, were increase
Ventures quarter, the of had the gains During investments portfolio we McKesson $X million in $XX second fiscal million to net related of to equity quarter of XXXX. approximately net losses within compared the
be by the the a consolidated results each As individual investment impacts performance can quarter-to-quarter. on influenced reminder, of
incurred The a by which Ventures in gains offset lower will expenses As result, $X in anticipate expenses litigation and of opioid-related second can investments the from be the timing our quarter. McKesson's million. partially that of for and each opioid-related may investment. magnitude litigation losses, the million we McKesson fiscal result vary quarter, in litigation impact opioid-related expenses We portfolio or XXXX approximately year-over-year was $XX
Turning to Slide on XX. be position, found which cash our can now
position, cash cash each be equivalents. our vary capital metrics can We billion with timing reminder, and cash and quarter-to-quarter. by ended from impacted $X.X in quarter the resulting flows cash and a As working
first in and expenditures, technology, growth automation data investment services and including million capital distribution capacity priorities, oncology six ecosystems. center and to the biopharma our fiscal $XXX support made we in which investments and the year, months include During of analytics of
we For had and And $X.X our Year-to-date, cash and payments. $XXX in the billion we we and which $X.X repurchases $X.X of million, billion free to billion months first share repurchase of dividend XXXX returned negative authorization. $XXX fiscal million have respectively. our $XX XXXX, on cash remaining six included of of share million shareholders, flow
begin full outlook. And presentation. XXXX our supplemental on I'll XX with our in fiscal Slides assumptions list our outlook. now can A Let found me through turn XX consolidated be of to our slide
XXXX. to to fiscal X% XXXX to fiscal X% growth X% compared and X% guidance decline assumes growth for revenue profit Our operating
Let COVID-XX for updated programs. me guidance from provide contribution
in items: $X.XX vaccine related $X.XX Solutions U.S. ancillary to segment; million of $XXX U.S. $X.XX $X.XX includes Pharmaceutical equity of we to following to $X.XX tests government's our which the losses the guidance to reported of the Surgical our distribution $X attributable anticipate distribution We to contribution the in investments. Medical related to storage corporate the McKesson revised approximately in COVID-XX kitting and includes associated segment; fiscal year. and Our $X.XX to and McKesson Ventures million, losses $XXX investments, associated first half in range Ventures expenses of of with net which net equity the supplies with
me heard to you've include predict gains when not and been occur, it's difficult may Ventures say companies on storage portfolio losses and will As end excluding distribution before, When the our kitting, COVID-XX and continue and U.S. the and government's practice in operating the Ventures McKesson distribution portfolio tests to vaccine the estimates has equity Ventures centralized we our with XX%. net therefore, associated investments, guidance. increase profit anticipate X% to ancillary supplies, McKesson test gains the COVID-XX losses to impacts of or related and to
to Solutions million. to We Moving new in guidance expense line. our increase below the to reflects compared $XXX $XXX interest Savings prior million debt. Rx anticipate the acquisition the with The be of range intent to
range PHOENIX of full our and reduced the second anticipated And the the European guidance for our including the with XXXX of our International continued to COVID-XX-related quarter to range $XX.XX increasing performance, previous based the transaction remains items, are $XX.XX of results operating we to to earlier-than-expected and includes from increased Our solid approximately outlook effective year narrowing Group. contribution from closing XX% on segment tax rate unchanged. a of $XX.XX also in guidance from $XX.XX. fiscal the The XX% range
earnings investments XXXX to XXXX our the fiscal fiscal items COVID-XX-related gains and of year. prior growth XX% growth indicates communicated losses fiscal net and outlook the both and it XX% previously commitment This approximately demonstrates impacts from the targets, Ventures deliver to with Excluding results, from and sustainable long-term adjusted guidance XXXX growth. the equity aligns McKesson over guidance
the segment outlook. Moving now to
resonate retail, Health our was to pleased services to be growth principle continue our of agreement and The across CVS settings. are the segment. continue of June solutions we health by distribution through in The systems distribution the with to pharmaceutical our platform with and U.S. extend in value seeing breadth Pharmaceutical recent XXXX. of We the core exemplified provider partnership
We XXXX venture in position Sarah Oncology anticipate to ecosystem, leadership growth fiscal across Research U.S. accelerate further Research extend oncology. Cannon the And joint McKesson's and further in HCA intend to between second our oncology we also half investments including a operating our Institute. of expense
on trajectory of segment Our XX% and anticipate in to XX% profit our ranges. to increase positive this is outlook the increase to growth reported updated reflected to We X%. revenue X% operating
XX% As earlier, government, the impact X% vaccine to Solutions COVID-XX When to contract $X.XX X% includes extension profit to growth anticipate operating and COVID-XX revenue we of for government, U.S. $X.XX to approximately Technology which related the our Prescription result segment, July outlined to XX%. the of we anticipate of long-term profit operating vaccine I XX% to outlook U.S. distribution growth growth, the distribution XXXX. XX% is the a through above of of the previously growth target. In disclosed excluding
access, the of capabilities. assumed affordability This capabilities accelerates and The acquisition in continues patients. invest perform build for to Savings our to and trajectory with line increasing continue to adherence will solutions over We Solutions last Rx few focus segment X%. anticipate revenues decrease in our the we to decrease outlook, the focus. to X% Surgical X% In reported its to and and years long-term the reflects profit ongoing and operating to growth Solutions investment X% Medical segment, on
U.S. which our incorporates of the mentioned, the tests and the the for distribution and $X.XX to U.S. COVID-XX contract government, storage previously approximately government to supplies XXXX. outlook $X kitting, ancillary with As related extension to includes January of
anticipate profit to increase Surgical XX% COVID-XX Medical items, Excluding operating related the to impact we of XX%.
by the recently XX% anticipate businesses XX%. segment, contribution closed to profit XX% have to includes year-over-year the revenues to closed decline to transactions decline from we PHOENIX of Finally, operating we including the by in with loss International XX% profit operating the to transaction decrease date, This and and Group.
year-to-date For contributions with contribution fiscal of operations anticipate the to in profit held-for-sale accounting nine $X from completed primarily we per PHOENIX approximately fiscal Norway and sales, prior operations operating will XXXX, contribute to Group. share $X.XX for transaction our in our the includes year. the first diluted European related months of This to operations the
closed to this the we and PHOENIX This the transaction profit Group. segment. guidance We negatively for have driver change than behind impacting pleased is earlier main transaction are guidance, the closed the in with prior had operating anticipated,
Let In timing by XXXX XXXX, review progression, including activity transactions. flows, a with and my flow and of remarks been me cash conclude the deployment. and have cash divestiture fiscal capital impacted other European our outlook fiscal
billion we is approximately acquisitions XXXX, continue to net software capitalized and free which fiscal $X.X billion, For to of anticipate $X.X flow cash property expenses. of
flow Our and continue operations from businesses of negative free our cash divested approximately American North our European free strong million generate cash assets. guidance $XXX to includes flow. impacts
allocation balance us capital to multiple affords Our and priorities remain strong priorities the allocation capital pursue flexibility concurrently. our sheet unchanged,
will and biopharma with venture prioritize and Institute, areas Savings growth, to acquisition Canon as the We in the of the joint Sarah principally the Research Genospace services, evidenced acquisition Rx our continue oncology of by Solutions. of
to also returning We committed remain our shareholders. to capital
end we shares fiscal XXXX, approximately plans incorporates fiscal will our which $X.X third of be largely outlook complete to of anticipate the in Our billion repurchase by quarter.
our first earnings half guidance. strategies raise to us of to range the the outstanding shares be activity, of fiscal confidence are of we capabilities and diluted for of fiscal we execution million. the share approximately XXXX estimate result products million As with $XXX and of in performance. In weighted value our gives the repurchase summary, strength our $XXX our pleased average XXXX proven model, The and the to visibility business a our
growth, create cash generation We our for value continue and through flow capital. return to of solid shareowners
turn that, across that the McKesson results. Q&A. operator And Our the confidence the strong leadership continue back call I'll ongoing deliver will with to tremendous over sustainable commitment of we people to and our us for gives
